Loading...

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Posters by Code

Showing 1,267 results.

Thumbnail for Preclinical Evaluation of INCA035784, a Novel T-Cell-Redirecting Antibody for the Treatment of MutCALR-Driven Myeloproliferative Neoplasms (MPNs)

MPN - 553

Preclinical Evaluation of INCA035784, a Novel T-Cell-Redirecting Antibody for the Treatment of MutCALR-Driven Myeloproliferative Neoplasms (MPNs)

Liang-Chuan Wang

Poster Presenter: Liang-Chuan Wang

Thumbnail for Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, Is Well Tolerated and Achieves Robust Spleen, Anemia, and Molecular Responses in Patients With Myelofibrosis

MPN - 554

Mutant Calreticulin-Specific Monoclonal Antibody, INCA033989, Is Well Tolerated and Achieves Robust Spleen, Anemia, and Molecular Responses in Patients With Myelofibrosis

Tania Jain

Poster Presenter: Tania Jain

Thumbnail for Trial in Progress: A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naive Adult Patients With Myelofibrosis (MANIFEST-3)

MPN - 555

Trial in Progress: A Phase 3, Randomized, Double-Blind, Active-Control Study of Pelabresib (DAK539) Plus Ruxolitinib vs Placebo Plus Ruxolitinib in JAK Inhibitor-Naive Adult Patients With Myelofibrosis (MANIFEST-3)

John Mascarenhas

Poster Presenter: John Mascarenhas

Thumbnail for Mutant Calreticulin-Specific Monoclonal Antibody INCA033989 Produces Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis

MPN - 556

Mutant Calreticulin-Specific Monoclonal Antibody INCA033989 Produces Molecular Responses That Correlate With Clinical Responses in Patients With Myelofibrosis

John Mascarenhas

Poster Presenter: John Mascarenhas

Thumbnail for Healthcare Provider Perspectives on the Therapeutic Phlebotomy Workflow in Polycythemia Vera and Associated Resource Use in the United States

MPN - 558

Healthcare Provider Perspectives on the Therapeutic Phlebotomy Workflow in Polycythemia Vera and Associated Resource Use in the United States

Naveen Pemmaraju

Poster Presenter: Naveen Pemmaraju

Thumbnail for How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real-World Evidence From the Targeted Therapy Era

CLL - 560

How Many Lines of Therapy Do Patients With CLL/SLL Receive in Routine Clinical Practice in the United States? Real-World Evidence From the Targeted Therapy Era

Deborah M. Stephens

Poster Presenter: Deborah M. Stephens

Thumbnail for Predictors of Long-Term Response to Olutasidenib in Mutant IDH1 Acute Myeloid Leukemia (AML)

AML - 562

Predictors of Long-Term Response to Olutasidenib in Mutant IDH1 Acute Myeloid Leukemia (AML)

Amber Thomasson

Poster Presenter: Amber Thomasson

Thumbnail for Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib

MPN - 564

Real-World Treatment Patterns and Outcomes in Patients With Myelofibrosis Treated With First-Line Pacritinib or Ruxolitinib

Naveen Pemmaraju

Poster Presenter: Naveen Pemmaraju

Thumbnail for Hematologic Manifestations and Clonal Hematopoiesis in Telomere Biology Disorders: A Retrospective Single-Center Cohort Study

MDS - 565

Hematologic Manifestations and Clonal Hematopoiesis in Telomere Biology Disorders: A Retrospective Single-Center Cohort Study

Olisaemeka Ogbue

Poster Presenter: Olisaemeka Ogbue

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.